Metagenomi Therapeutics (MGX) Preferred Stock Liabilities (2023)
Metagenomi Therapeutics (MGX) reported Preferred Stock Liabilities of $350.8 million for Q4 2023, little changed quarter-over-quarter from $350.8 million in Q3 2023.
Metagenomi Therapeutics (MGX) Preferred Stock Liabilities (2023) Analysis & Trends
Metagenomi Therapeutics (MGX) has 1 years of Preferred Stock Liabilities data on file, last reported at $350.8 million in Q4 2023.
- Preferred Stock Liabilities for Q4 2023 came in at $350.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $350.8 million (changed N/A YoY), and the FY2023 annual result was $350.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $350.8 million in Q4 2023 per MGX's latest filing, from $350.8 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $350.8 million in Q1 2023 and troughed at $350.8 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 350.76 Mn |
| Sep 30, 2023 | 350.76 Mn |
| Jun 30, 2023 | 350.76 Mn |
| Mar 31, 2023 | 350.76 Mn |